Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company dev…

Biotechnology

US, Boulder [HQ]

Board & Officers
Business Intelligence
Employee Voice
Mergers and Acquisitions
Qualified Risks
ESG Scores [Soon]

Strategy & Leadership

Officers & BofD Beta

All directors and officers of Fresh Tracks Therapeutics, Inc. are sourced directly from the SEC or manually.
For the SEC we either use the Form 3/4/5 or, even better extract the compensation for each leader out of the audited proxy statement (DEF-14A).

Form 3/4/5
Proxy DEF-14A

Total Compensation

Shows the total compensation per mentioned executive and board director.
Each datapoint refers the most recent appearance of the corresponding person.

- No data, only available if we have DEF 14A compensations in place -

Officers

Name & Position	Research
Fox-Collis Aaron VP of Finance & CAO	Transactions Compensations Speech	01/09/24 [Form 4]
Marchio Albert N Ii CEO and CFO Also inside the BofD	Transactions Compensations Speech	01/09/24 [Form 4]
Chadha Deepak Former Chief R&D Officer & COO	Transactions Compensations Speech	12/11/23 [Form 4]
Sklawer Andrew D President and CEO	Transactions Compensations Speech	10/04/23 [Form 4]
Mcavoy David R. Gen Counsel, CCO, & Secretary	Transactions Compensations Speech	10/04/23 [Form 4]
Hardy Reginald L CHAIRMAN OF THE BOARD Also inside the BofD	Transactions Compensations Speech	05/17/22 [Form 4]
Breton Jose Chief Accounting Officer	Transactions Compensations Speech	05/09/22 [Form 4]
Luchi Monica E. Chief Medical Officer	Transactions Compensations Speech	05/09/22 [Form 4]
Brown Robert Busard Chief Executive Officer Also inside the BofD	Transactions Compensations Speech	05/09/22 [Form 4]

Board of Directors (BofD)

Name & Position	Research
Samant Vijay B Director	Transactions Compensations Speech	05/17/22 [Form 4]
Lyons Gary A Director	Transactions Compensations Speech	05/17/22 [Form 4]
Veru Dennison T Director	Transactions Compensations Speech	05/17/22 [Form 4]